Latest On Transgene SA (TRGNF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2022-11-07 13:45 EST | News | Transgene S.A. reports Q3 results | N/A |  |
| 2021-12-15 04:22 EST | News | AstraZeneca exercises license option for Invir.IO oncolytic virus generated by Transgene | N/A | |
| 2021-11-22 17:24 EST | News | Transgene reports positive early data from phase 1 trial of cancer vaccine | N/A | |
| 2021-09-22 19:00 EST | News | Transgene SA 2021 Q2 - Results - Earnings Call Presentation | N/A | |
| 2021-09-01 17:29 EST | News | Transgene joins PERSIST-SEQ international cancer research consortium | N/A | |
| 2021-07-22 17:09 EST | News | FDA approves BioInvent/Transgene's application for BT-001 in solid tumors | N/A | |
| 2021-07-22 17:07 EST | News | Transgene enrolls first patient in mid-stage TG4001 cancer trial | N/A | |
| 2021-03-12 17:57 EST | Financials | Company financials have been released. | Neutral | |
| 2021-03-11 01:32 EST | News | Transgene expands mid-stage TG4001 cancer study | N/A | |
| 2021-03-01 11:34 EST | News | Enrollment underway in BioInvent/Transgene's BT-001 trial in solid tumors | N/A | |
| 2021-01-19 08:08 EST | News | Transgene and BioInvent on go with study of BT-001 in solid tumors | N/A | |
| 2020-12-04 06:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-27 00:47 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 00:34 EST | News | Transgene provides Q3 update | N/A | |
| 2020-10-08 21:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-10-07 08:05 EST | News | Transgene teams up with NEC and BostonGene for ovarian and head & neck cancer studies | N/A | |
| 2020-10-04 15:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 16:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-22 20:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 09:18 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 12:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 16:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-05 05:40 EST | News | Transgene offloads some shares in Tasly BioPharmaceuticals | N/A | |
| 2020-08-04 19:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 12:07 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-31 04:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 20:43 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 08:31 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 00:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-28 16:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 16:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 21:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 17:07 EST | News | Transgene up 9% on positive HPV therapeutic vaccine data | N/A | |
| 2020-07-09 12:35 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 07:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-02 23:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 20:14 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 04:06 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-25 07:28 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 16:05 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 08:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 09:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-07 19:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-05 15:36 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-03 19:27 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 08:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 04:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-14 03:55 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 11:38 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-07 04:23 EST | News | Transgene S.A. reports Q1 results | N/A | |
About Transgene SA (TRGNF):
Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company's lead clinical-stage programs include TG4010, a therapeutic vaccine for the treatment of non-small cell lung cancer; Pexa-Vec, an oncolytic virus for the treatment of liver cancer; and TG4001, a therapeutic vaccine for cancers caused by the human papilloma virus. Its products in the clinical development stage also comprise TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and TG6002, an oncolytic virus for the treatment of various solid tumors, such as glioblastoma, as well as for the cancers of the stomach, colon, pancreas, and bladder. Transgene SA has collaboration agreements with Bristol-Myers Squibb, Merck KGaA, Pfizer, and University of California Davis; licensing agreements with SillaJen, Inc. and Ascend BioPharmaceutical; agreements with Sanofi, BioInvent, Randox, and Emergent BioSolutions Inc.; collaboration and licensing agreement with Valneva; a strategic collaboration with NEC Corporation; and a collaboration with BioInvent International AB (publ) to co-develop multi-functional oncolytic viruses encoding for undisclosed antibodies sequences for treating a range of solid tumors. It also has a collaborative research and license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.
General
- Name Transgene SA
- Symbol TRGNF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Fiscal Year EndDecember
- Web URLhttp://www.transgene.fr
Valuation
- Trailing PE 14.33
- Price/Sales (Trailing 12 Mt.) 33.82
- Price/Book (Most Recent Quarter) 3.49
- Enterprise Value Revenue 35.12
- Enterprise Value EBITDA 18.93
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin -184%
- Return on Assets -15%
- Return on Equity -30%
- Earnings Per Share -$0.52
- Revenue Per Share $0
- Gross Profit -18003000
- Quarterly Earnings Growth -52.7%
Highlights
- Market Capitalization 272.4 million
- Book Value Per Share $0.26
Share Statistics
- Shares Outstanding 83.84 million
- Shares Float 27.85 million
- % Held by Insiders 6492%
- % Held by Institutions 0.72%
Technicals
- Beta 0.88
- 52 Week High $3.22
- 52 Week Low $1.15
- 50 Day Moving Average 3.04
- 200 Day Moving Average 2.93
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Transgene SA (TRGNF) Dividend Calendar:
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Transgene SA (TRGNF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-09-30 | 2020-12-31 | $N/A | -$0.11 | $0.00 | |
| 2020-06-30 | 2020-09-30 | $N/A | -$0.11 | $0.00 | |
| 2020-03-31 | 2020-06-30 | $N/A | -$0.02 | $0.00 | |
| 2019-12-31 | 2020-03-31 | $15.31 million | -$0.02 | $0.00 | |
| 2019-09-30 | 2019-12-31 | $11.22 million | -$0.02 | $0.00 | |
| 2019-06-30 | 2019-09-30 | $8.69 million | -$0.02 | $0.00 | |
| 2019-03-31 | 2019-06-30 | $8.1 million | -$0.14 | $0.00 | |
| 2018-12-31 | 2019-03-31 | $2.09 million | -$0.14 | $0.00 | |
| 2018-09-30 | 2018-12-31 | $2.11 million | $0.21 | $0.00 | |
| 2018-06-30 | 2018-09-30 | $2 million | $0.22 | $0.00 | |
| 2018-03-31 | 2018-06-30 | $2.12 million | -$0.14 | $0.00 | |
| 2017-12-31 | 2018-03-31 | $2.38 million | -$0.15 | $0.00 | |
| 2017-09-30 | 2017-12-31 | $2.32 million | -$0.12 | $0.00 | |
| 2017-06-30 | 2017-09-30 | $2 million | -$0.12 | $0.00 | |
| 2017-03-31 | 2017-06-30 | $1.86 million | -$0.19 | $0.00 | |
| 2016-12-31 | 2017-03-31 | $2.53 million | -$0.18 | $0.00 | |
| 2016-09-30 | 2016-12-31 | $2.53 million | -$0.09 | $0.00 | |
| 2016-06-30 | 2016-09-30 | -$0.09 | $0.00 | ||
| 2016-03-31 | 2016-06-30 | -$0.17 | $0.00 | ||
| 2015-12-31 | 2016-03-31 | -$0.17 | $0.00 | ||
| 2015-09-30 | 2015-12-31 | -$0.23 | $0.00 | ||
| 2015-06-30 | 2015-09-30 | -$0.24 | $0.00 | ||
| 2015-03-31 | 2015-06-30 | -$0.31 | $0.00 | ||
| 2014-12-31 | 2015-03-31 | -$0.30 | $0.00 | ||
| 2014-09-30 | 2014-12-31 | -$0.31 | $0.00 | ||
| 2014-06-30 | 2014-09-30 | -$0.33 | $0.00 | ||
| 2014-03-31 | 2014-06-30 | -$0.38 | $0.00 | ||
| 2013-12-31 | 2014-03-31 | -$0.38 | $0.00 | ||
| 2013-09-30 | 2013-12-31 | -$0.43 | $0.00 | ||
| 2013-06-30 | 2013-09-30 | -$0.42 | $0.00 | ||
| 2013-03-31 | 2013-06-30 | -$0.48 | $0.00 | ||
| 2012-12-31 | 2013-03-31 | -$0.47 | $0.00 | ||
| 2012-09-30 | 2012-12-31 | -$0.44 | $0.00 | ||
| 2012-06-30 | 2012-09-30 | -$0.43 | $0.00 | ||
| 2012-03-31 | 2012-06-30 | -$0.43 | $0.00 | ||
| 2011-12-31 | 2012-03-31 | -$0.46 | $0.00 | ||
| 2011-09-30 | 2011-12-31 | -$0.53 | $0.00 | ||
| 2011-06-30 | 2011-09-30 | -$0.55 | $0.00 | ||
| 2011-03-31 | 2011-06-30 | -$0.41 | $0.00 | ||
| 2010-12-31 | 2011-03-31 | -$0.40 | $0.00 | ||
| 2010-09-30 | 2010-12-31 | -$0.42 | $0.00 |
Transgene SA (TRGNF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | N/A | -16.2 million |
| Income Before Tax | N/A | N/A | N/A | N/A | -6.09 million |
| Selling General Administrative | N/A | N/A | N/A | N/A | 6.27 million |
| Gross Profit | N/A | N/A | N/A | N/A | -31.01 million |
| Ebit | N/A | N/A | N/A | N/A | -21.17 million |
| Operating Income | N/A | N/A | N/A | N/A | -21.17 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | N/A | 15.31 million |
| Cost of Revenue | N/A | N/A | N/A | N/A | 46.33 million |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 15.08 million |
| Net Income From Continuing Operations | N/A | N/A | N/A | N/A | -6.09 million |
| Net Income Applicable to Common Shares | -7.51 million | -7.51 million | -1.11 million | -1.11 million | -1.94 million |
Cash Flow:
| Date | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 | Jun 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -1.95 million | -1.43 million | 2.09 million |
| Change to Liabilities | -1.87 million | -1.87 million | -1.27 million | -1.24 million | 5.08 million |
| Total Cash Flow from Investing Activities | -107500 | -107500 | -786523.15 | -764577.66 | 492043.79 |
| Net Borrowings | 2.66 million | 2.66 million | 228164.59 | 221798.37 | 1.52 million |
| Total Cash Flow from Financial Activities | N/A | N/A | 10.52 million | 7.71 million | 31.05 million |
| Change to Operating Activities | -1.39 million | -1.39 million | -2.44 million | -2.37 million | -1.52 million |
| Change in Cash | N/A | N/A | -18.24 million | -13.36 million | 18.58 million |
| Total Cash from Operating Activities | -7.86 million | -7.86 million | -8.38 million | -8.14 million | -4.22 million |
| Depreciation | N/A | N/A | 1.48 million | 1.09 million | -136142.08 |
| Other Cash Flow from Investing Activities | N/A | N/A | 672721.16 | 653950.95 | 677124.48 |
| Change to Inventory | N/A | N/A | 735645.31 | 538864.39 | 47271.55 |
| Change to Account Receivables | N/A | N/A | -1.05 million | -768332.98 | -1.27 million |
| Other Cash Flow from Financing Activities | 8.23 million | 8.23 million | -24.18 million | -23.51 million | 7.75 million |
| Change to Net Income | -4.3 million | -4.3 million | -3.3 million | -3.21 million | 853176.84 |
| Capital Expenditures | N/A | N/A | 2.6 million | 1.91 million | 397081.06 |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | N/A | 49.78 million |
| Total Stockholder Equity | N/A | N/A | N/A | N/A | 65.7 million |
| Other Current Liabilities | 7.14 million | 7.14 million | N/A | N/A | 33.5 million |
| Total Assets | N/A | N/A | N/A | N/A | 115.48 million |
| Common Stock | 41.92 million | 41.92 million | 41.92 million | 41.92 million | 83.27 million |
| Other Current Assets | 2.67 million | 2.67 million | N/A | N/A | 35000 |
| Retained Earnings | -31.56 million | -31.56 million | -16.54 million | -16.54 million | -56.25 million |
| Other Liabilities | 4.64 million | 4.64 million | 4.52 million | 4.52 million | 4.43 million |
| Other Assets | 7.47 million | 7.47 million | 4.01 million | 4.01 million | 9.48 million |
| Cash | N/A | N/A | N/A | N/A | 1.34 million |
| Total Current Liabilities | 13.63 million | 13.63 million | N/A | N/A | 18.65 million |
| Other Stockholder Equity | -1.05 million | -1.05 million | -1.03 million | -1.03 million | -1.06 million |
| Property, Plant & Equipment | 13.11 million | 13.11 million | 13.68 million | 13.68 million | 13.28 million |
| Total Current Assets | 30.69 million | 30.69 million | N/A | N/A | 49.64 million |
| Long Term Investments | N/A | N/A | N/A | N/A | 151.11 million |
| Net Tangible Assets | 50.11 million | 50.11 million | 64.17 million | 64.17 million | 65.55 million |
| Short Term Investments | N/A | N/A | N/A | N/A | 42.03 million |
| Long Term Debt | N/A | N/A | N/A | N/A | 22.13 million |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | 5.07 million | 5.07 million | N/A | N/A | 7.09 million |
Transgene SA (TRGNF) Chart:
Transgene SA (TRGNF) News:
Below you will find a list of latest news for Transgene SA (TRGNF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Transgene SA (TRGNF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Transgene SA (TRGNF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|